Retatrutide Triple-Receptor Weight Loss, Liver Fat, and Dose Logic

Retatrutide Dosage by Body Type

The dose that produced 24% weight loss in the Phase 2 trial was measured in one kind of body: average BMI 37, around 110 kg, sedentary, non-diabetic.⁶ A 75 kg lean person taking the same milligrams is not taking the same drug. The chart below is therefore built by body type rather than presented as one ladder with footnotes.

Two things shift the moment the body changes. A lighter body has less blood to dilute the dose: against the 98 kg average of the trial that measured retatrutide’s blood levels, a 75 kg person sees about 24% more drug per milligram and a 70 kg person about 31% more.⁷ (Every exposure multiplier here indexes to that 98 kg pharmacokinetic cohort. The 110 kg figure above is the separate weight-loss trial, which sits about 9% below the same reference.) The larger difference is the heart. A metabolically healthy cardiovascular system reads the same glucagon signal far harder, and a lean user has no large weight loss to bring the rate back down.⁸

Trial-cohort obese — BMI 30 to 40, non-diabetic. The published anchor. A practical start is 0.5 mg, building through 1, 1.5, 2, 2.5, 3, 3.5, then 4 or 5 mg, holding four weeks per step. The 1 mg arm is the lowest dose with direct human weight-loss data: 8.7% at 48 weeks.⁶ The 6 to 9 mg band is high-efficacy territory for higher adiposity, fatty liver, or a stalled response.

Metabolically healthy lean — BMI 22 to 28. Protocols in this range start at 0.3 mg. The effective bands compress: meaningful results appear at 2 to 4 mg rather than 6 to 8 mg, and heart rate rather than nausea is the limiting cost, which makes a weekly resting-pulse reading through each increase the measurement that matters. No chronic trial enrolled this phenotype. The bands come from the receptor pharmacology and the Phase 1 single-dose cohort, which was lean.

Type 2 diabetic obese — BMI 30 to 40. Blood-sugar improvement is the loud signal here. At 4 mg, HbA1c fell 1.39% by week 24; at week 36 it was down 1.30% with dose escalation and 1.50% without escalation.⁹

Years of high glucose blunt part of the GIP response, but retatrutide’s high GIP-receptor engagement pushes through some of that. The heart-rate signal is quieter than in lean users, because long-standing metabolic disease blunts the cardiovascular response, while the kidney and liver benefits of the glucagon arm are central for this group.

Across every body type the ladder reads in four lanes:

• Microdose, 0.3 to 1 mg. GIP-forward. The liver and visceral-fat signal begins and appetite eases without forcing.
• Standard, 1 to 5 mg. The main weight-loss range, where appetite suppression establishes and the glucagon arm builds.
• High-efficacy, 6 to 9 mg. Added weight loss comes from appetite and glucagon signal; the GIP arm is saturated. 9 mg is the routine high-dose target in Phase 3.
• Escalation, 10 to 12 mg. The 8 to 12 mg step buys little extra average weight loss for a real increase in side effects. It matters mainly for the deepest responders and for liver and visceral-fat goals.

Hold each dose for at least four weeks before increasing. Retatrutide’s six-day half-life means a new dose does not reach steady plasma levels for almost three weeks, which puts the heart-rate or nausea response to one step after the point at which a fast titration has already moved to the next.¹⁰

Speed matters more than the destination. In the Phase 2 trial, the arm that jumped in 4 mg steps carried sustained gastrointestinal symptoms across all 48 weeks, while every slower arm faded to single-digit rates by month nine — same drug, same final dose, different tolerability.⁶ The proposed mechanism is a brainstem circuit that GIP activates to buffer nausea, and which needs weeks of low GLP-1 load to establish. That circuit is measured; the weeks-long wiring window is inferred from the trial pattern rather than measured directly.¹

A 2026 analysis across approved incretin drugs found that longer escalation and more dose steps tracked greater nausea and vomiting tolerance, but retatrutide was not included in that analysis.²¹

Two practical consequences follow. Do not skip bridge rungs on the way up; the calculator inserts 5 and 6 mg steps before 8 or 9 mg for that reason. And consider splitting the weekly dose at 4 mg and above.

At the same weekly total, dosing every three days cuts the modeled peak-to-trough excursion to about 43% of the weekly swing. The modeled steady-state peak itself falls only about 19%, because the trough rises and the smaller injections accumulate toward nearly the same ceiling. The result is a flatter curve with the same cumulative exposure.²²

The headline figures are the Phase 2 obesity result of 24.2% mean weight loss at 12 mg over 48 weeks, and the Phase 3 TRIUMPH-4 result of 28.7% at 12 mg over 68 weeks in obesity with osteoarthritis.⁶ ¹¹ Across the dose range, the response follows a curve rather than a straight line: half of the maximum effect arrives by about 4 mg, and 8 mg already captures roughly 94% of what 12 mg delivers.⁴ ¹²

The trajectory is gradual. Weight loss at week 24 is roughly three-quarters of the eventual result, appetite reaches most of its long-run effect by week 24, and liver-fat reduction is still moving at week 48. Two person-level factors move the expected number more than most people assume. Women lose meaningfully more than men at the same dose, with the female advantage in obesity around 4 kg, the largest of any compound studied.¹³ And the effect declines with age, by roughly 3% for each year above 50, independent of body type.¹²

These figures come from the trials. A lean recomposition user starting at a normal body weight should expect a smaller absolute loss in kilograms, though it can be proportionally meaningful, and no chronic trial has measured that population directly.

Retatrutide and Liver Fat

The glucagon arm is what makes retatrutide a liver drug, not only a weight drug. Glucagon signals the liver to oxidize its own stored fat, an effect semaglutide and tirzepatide cannot produce because they do not engage the glucagon receptor.³

In the MASLD substudy, which enrolled only people with at least 10% liver fat, liver fat fell 51% at 1 mg and 86% at 12 mg over 48 weeks, and steatosis resolved in 93% of participants at the top dose.¹⁴ The effect is substrate-gated. A person with a fatty liver has fat to mobilize, and the reduction is large and measurable. A lean person without liver fat shows the same biochemical signal of fat-burning, a rise in ketones, but has no stored liver fat to deplete, leaving a liver-fat scan with little to register. The same glucagon engagement, read through a different liver, gives a different result.

The glucagon arm also lowers triglycerides and LDL cholesterol by releasing the brake on an enzyme that clears fat from the blood, with triglycerides falling around 60% and LDL around 25% at the top dose.¹⁵

Body Composition and Titration Speed

Retatrutide-specific body composition was measured by DXA in a Phase 2 substudy of adults with type 2 diabetes. Fat mass, lean mass, and visceral fat all fell by week 36, with fat accounting for most of the measured loss. The substudy compared dose groups, not titration paths.¹⁹

The obesity trial established a titration-speed difference in gastrointestinal burden, but it did not measure body composition. Its waist and weight trajectories cannot show that slow titration preferentially preserved lean mass or that fast titration shifted loss toward water and muscle.

Across the class, roughly a quarter of weight lost is fat-free mass, and about half of that is skeletal muscle.¹⁶ For a heavier person this is a small fraction of a large loss. For a lean user with less reserve, it is a higher-resolution concern, which is one more reason the lean phenotype favors a slower, lower-dose approach with resistance training and adequate protein.

Side effects on retatrutide come from two receptor sources. The GLP-1 arm drives the familiar gastrointestinal effects: nausea, vomiting, diarrhea, and slowed digestion. These scale with dose, peak during titration, and partially settle over time; slow titration and smaller, protein-anchored meals are the main levers.

The same GLP-1 arm drives a less familiar effect at the upper doses: a burning or tingling skin sensitivity (dysesthesia). It is not the glucagon arm — high-dose semaglutide, which has effectively no glucagon action, carries it too, which puts the effect on the GLP-1 class rather than the glucagon arm. Selective ATP/P2X sensory amplification is the candidate mechanism.¹⁷

Where it becomes common is a step, not a slope. Across the obesity program, rates run near placebo at 1 mg (1.4%), reach about 6% at 4 mg, then step up sharply at the 8 and 9 mg rung — 12.3% at 9 mg in Phase 3, 12.9% at 12 mg in Phase 2, and 20.9% at 12 mg in the osteoarthritis trial. In exposure terms the break sits around 70 to 80 µg per kilogram of body weight. That framing matters for lighter users: at 70 kg, 9 mg delivers about 129 µg/kg, well past the break, putting a lighter person into the high-rate band at a lower milligram number than the trial average did.

Escalation speed appears to be a modifiable lever, not just the final dose. In Phase 2, two arms reached the same 8 mg destination by different paths: the slower ramp carried 2.9% dysesthesia, the faster one 14.3%. Those are 1 and 5 events on 35 participants each, which makes the comparison suggestive rather than settled — but it points the same direction as the gastrointestinal data, where the slower ramp to 8 mg produced 16.7% peak burden against 36.9% on the double step. The effect is usually mild and eases after dose reduction.¹⁷

Cold intolerance and the fatigue that travels with it have a mechanism worth understanding, because it determines which test is informative. Heat production in brown fat is gated locally, by an enzyme called DIO2 that amplifies thyroid hormone inside the tissue three- to four-fold — not by the thyroid hormone level circulating in blood. Three separate retatrutide effects converge on that same local gate: FGF21 falls dose-dependently, reaching −65.7% at 8 mg, and FGF21 is what supports DIO2 in thermogenic tissue; the glucagon arm lowers T3 and raises reverse-T3 in humans with no change in TSH; and the energy deficit itself drops the thyroid axis, the way 72 hours of fasting cuts T3 by about 30%. Two further routes skip thyroid entirely — GLP-1 raises skin blood flow, shedding heat where cold is actually felt, and suppresses brown-fat activity through nerve signaling.²⁰

The practical consequence is a specific testing choice, because those routes predict different signatures and one measurement pair separates them.

The thyroid route reads as T3 down and reverse-T3 up with TSH unchanged, alongside cold skin and a widened gap between core and skin temperature. The perfusion route reads as an intact thyroid panel with warm skin that nonetheless feels cold, and a narrowed gap. Onset timing separates them further: the deficit route tracks how fast weight is coming off, the glucagon route tracks days after a dose step, and perfusion tracks injection timing.

The trap is that TSH does not move on this route. A TSH-first screen — which is what most labs reflex on — will read normal and stop. The panel has to specify Free T3 and reverse T3 to see the inversion at all. One caveat runs the other direction: because DIO2 amplifies thyroid hormone locally, a normal Free T3 does not fully exclude impaired heat production in the tissue. It does point toward perfusion rather than thyroid, which is still a useful narrowing.

Rising energy expenditure does not contradict any of this. Total energy burned, defended core temperature, peripheral heat loss, and thermal comfort are four separate variables: a body can burn more while defending temperature worse and shedding it faster.

A baseline panel before starting makes every later decision interpretable: resting heart rate recorded over a week, fasting glucose and HbA1c, a lipid panel, and liver enzymes. Thyroid testing follows symptoms and clinical history.

Trial adverse-event tables are pre-specified inventories. An effect nobody listed for capture does not appear in the results, whether or not participants experienced it. Hair loss is the clearest example: it sits outside the retatrutide capture set entirely, which makes the published silence on it a fact about the trial design and not evidence that it does not happen.

A fuller treatment of each side effect lives in the dedicated retatrutide side-effects guide.

The heart-rate rise is real, and it is mostly the glucagon arm. The GLP-1 class on its own raises resting heart rate by only 2 to 4 bpm even at maximum dose, and that floor does not climb with dose. Glucagon does: infused alone in humans it raises heart rate 13.0 bpm, and 9.2 bpm even under beta-blockade, which is three to four times the entire GLP-1-only ceiling. Sympathetic activation is not the route — heart-rate variability and norepinephrine are both unchanged, and blocking the beta-1 receptor does not abolish the effect.⁸

Two instruments measure this and they give different numbers, and the distinction is worth keeping. In-clinic pulse in the Phase 2 obesity cohort rose in a clean dose-ordered line to +6.0 bpm at 12 mg by week 48, against +0.4 on placebo. Twenty-four-hour ambulatory monitoring, a more sensitive instrument, read +6.7 bpm at 12 mg at week 36 (95% CI 4.6 to 8.8, placebo +0.9). Both peak around week 24 and attenuate 40 to 50% by week 48 as substantial weight loss brings the system back toward balance.⁶

The phenotype split matters here more than anywhere, and it is quantified rather than qualitative. The obese sedentary non-diabetic response curve tops out around 10 bpm and needs roughly half of glucagon-receptor capacity to get halfway there; the lean curve tops out around 33 bpm and reaches halfway at about one-sixth that occupancy. The measured consequence at a shared dose: 1 mg read +0.7 bpm on ambulatory monitoring in the BMI-37 trial cohort, and +10.3 bpm as an eight-day average — peaking 15 to 20 bpm on days 4 to 6 — in the lean Phase 1 cohort. Same milligram, same receptor occupancy, two different instruments. Without a large weight loss there is also no compensating decline. The cost per beat is also real: each sustained extra beat per minute adds a modest daily energy demand from heart muscle. For users at 6 mg and above, a smartwatch ECG check at each step is worth doing, and pre-existing atrial fibrillation or known structural heart disease is a clear reason not to use retatrutide.

Microdosing Retatrutide

Microdosing retatrutide has the strongest evidence base of any microdose claim in the GLP-1 class, because the 1 mg arm was a directly measured trial arm rather than an extrapolation. At 1 mg the GIP receptor is already roughly half-engaged and the liver is already burning fat, while the appetite and heart-rate signals stay light.⁴ ⁶

A microdose is a different signal mix rather than a weak version of a full dose: weighted toward the GIP arm, carrying much less of the glucagon-driven heart-rate cost.

Much less is not none, and the lean instrument is where that shows. In the lean Phase 1 cohort, 0.3 mg raised pulse 7.2 bpm as an eight-day average and 1 mg raised it 10.0 bpm, both statistically clear on their own data. A microdose moves heart rate in a lean body, at the bottom of the ladder. A common lighter-user ladder runs 0.1, 0.3, then 0.5 mg with four weeks per step; 0.3 mg is the lowest rung with both a measured drug level and a measured pulse response, while 0.1 mg has characterised pharmacokinetics but only six participants on the pulse reading — too few to establish either an effect or its absence, and it carries no heart-rate expectation in either direction. Below 1 mg the weight-loss logic rests on Phase 1 exposure data and the receptor model rather than chronic outcome trials.

Stopping Retatrutide

Stopping retatrutide does not cause a physical withdrawal syndrome, but it does set up weight regain, and the pressure is expected to be stronger than with semaglutide or tirzepatide. Four forces converge. Appetite returns as the drug clears over about 30 days. Any lean mass lost during the deficit lowers daily energy use. Hunger-hormone signals stay elevated for up to a year after major weight loss.¹⁸ And, unique to retatrutide, the glucagon-driven defense of resting metabolism fades within weeks of the last dose, removing a support the other drugs never provided.

There is no published retatrutide taper. The framework below is reasoned from the dose-response data and from semaglutide and tirzepatide withdrawal trials. A taper is behavioral, not a detox: it buys 8 to 12 weeks of lower-but-present appetite suppression in which to rebuild lean mass and lock in eating and training habits. A practical shape is a maintenance hold at 2 to 4 mg, then a slow step-down, with resistance training and at least 1.2 g/kg of protein per day carrying the muscle-preservation load throughout.

Retatrutide vs Tirzepatide

The mechanistic difference is one receptor. Tirzepatide’s glucagon engagement stays under 0.3% of receptor capacity even at 15 mg, against roughly 12% for retatrutide at 12 mg — a forty-fold gap that functions as a missing arm rather than a weak one. Retatrutide is also more potent at the GIP receptor, and meaningful GIP signaling arrives at a fraction of the dose. The glucagon arm is what gives retatrutide its liver-fat reduction, its defense of resting metabolism, and its larger heart-rate cost.

The two also differ at the receptor they share, in a way raw engagement hides. Retatrutide engages more of the GLP-1 receptor per dose, but tirzepatide gets more lasting signal out of each receptor it engages, because it barely triggers the receptor’s own wind-down switch. Comparing the two on GLP-1 engagement alone therefore overstates retatrutide’s edge there. The real separation between them is the glucagon arm, not the GLP-1 one.

On weight loss the head-to-head trial has not read out yet. Cross-trial, tirzepatide produced about 21% at 15 mg over 72 weeks, while retatrutide produced 24% at 12 mg over 48 weeks in Phase 2 and 29% in Phase 3 TRIUMPH-4; the numbers favor retatrutide, but differences in cohort and trial length make a precise gap unreliable until the direct comparison reports.⁶ ¹¹ For switching, the key point is not to carry a maximum tirzepatide dose straight across. Tirzepatide builds tolerance to two of retatrutide’s three receptors but none to the glucagon arm, which is why protocols restart at 1 to 2 mg and give that new system time to adjust.

A full comparison lives in the dedicated retatrutide versus tirzepatide guide.

Frequently Asked Questions

References

¹ GIP receptor — fat-cell energy handling via SERCA-mediated futile calcium cycling, and brainstem GABAergic antiemetic buffering: Yu et al. 2025 Cell Metabolism; Hayes, Borner & De Jonghe 2021 Diabetes.

² GLP-1 receptor — appetite suppression at hypothalamic and brainstem sites, vagal-mediated gastric slowing, area-postrema nausea pathway: Secher et al. 2014 J Clin Invest; Holst 2007 Physiol Rev.

³ Glucagon receptor — hepatic fatty-acid oxidation, resting-energy-expenditure preservation, and the dose-scaling cardiac contribution; tonic chronic engagement via hepatocyte PDE4B/4D downregulation: Long et al. 2025; Goodman et al. 2025 Br J Clin Pharmacol.

⁴ Receptor potency and engagement by dose — GIPR functional potency roughly an order of magnitude higher than tirzepatide in the low-density cAMP assays; 8 mg captures ~94% of the 12 mg mean effect: Coskun et al. 2022 Cell Metabolism; Jastreboff et al. 2023 NEJM.

⁵ GLP-1-receptor occupancy approximately half-engaged at 12 mg, still on the climbing portion of its dose-response curve: receptor model from Coskun 2022 EC50 values and steady-state exposure.

⁶ Phase 2 obesity trial — dose-response weight loss and titration-speed adverse-event pattern: Jastreboff et al. 2023 NEJM 10.1056/NEJMoa2301972. This trial did not measure body composition.

⁷ Body-weight exposure shift — lighter body weight raises exposure per dose; derived from tirzepatide population pharmacokinetics and retatrutide allometric validation: Schneck & Urva 2024 CPT Pharmacometrics Syst Pharmacol.

⁸ Cardiac chronotropy — additive multi-receptor composite. The GLP-1R-only class (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) tops out at +2 to 4 bpm and does not climb with dose; glucagon carries the dose-scaling majority. Petersen et al. 2020 JAHA 9:e016828 measured glucagon infusion alone at +13.0 bpm (95% CI 8.0-18.0, P<0.001) and +9.2 bpm under esmolol β1-blockade, with HRV and norepinephrine unchanged — so the route is direct chronotropy, not sympathetic activation. Sinoatrial mechanism: Lubberding et al. 2024 Cardiovasc Res. Phenotype amplification (Hill parameters: obese sedentary non-diabetic Hmax 10 / K 0.50, anchored to Jastreboff week-48 pulse; lean Hmax 33 / K 0.085, anchored to the Coskun Phase 1 fit): Goodman et al. 2025 Br J Clin Pharmacol; Coskun et al. 2022 Cell Metabolism Figure S4C.

⁹ Phase 2 type 2 diabetes trial — HbA1c reduction by dose: Rosenstock et al. 2023 Lancet.

¹⁰ Six-day half-life and steady-state kinetics; titration adaptation timing: Coskun et al. 2022 Cell Metabolism.

¹¹ Phase 3 TRIUMPH-4 — 28.7% weight loss at 12 mg over 68 weeks in obesity with osteoarthritis: Eli Lilly press release, December 2025 investor.lilly.com.

¹² Class dose-response and age covariate — model-based meta-analysis, retatrutide Emax and ED50, ~3% effect decline per year above ~50: Guo et al. 2025.

¹³ Sex-stratified meta-analysis — female weight-loss advantage, ~4.2 kg at the obesity indication: Yang et al. 2025 J Diabetes.

¹⁴ MASLD substudy — liver-fat reduction by dose and steatosis-resolution rate: Sanyal et al. 2024 Nature Medicine s41591-024-03018-2.

¹⁵ Lipid mechanism — glucagon-driven ANGPTL3/8 suppression, triglyceride and LDL reduction: Wen et al. 2025 Diabetes Obes Metab.

¹⁶ Lean-mass partition — roughly 25% of weight loss as fat-free mass, about half skeletal muscle, across the GLP-1 class: Nuijten et al. 2022 Obes Rev; Conte et al. 2024 JAMA.

¹⁷ Dysesthesia as a GLP-1-class effect at upper doses — not the glucagon arm (high-dose semaglutide, which reaches no meaningful glucagon engagement, carries the strongest signal in the class). Anand et al. 2018 PLoS ONE found enhanced ATP responses in human sensory neurons without direct nociceptor excitation or a TRPV1 effect; ATP/P2X amplification is the candidate mechanism. Frey et al. 2026 medRxiv reported incident allodynia HR 2.15 against an active weight-loss comparator (bupropion-naltrexone), which excludes weight loss itself as the cause. Program rates by arm — Jastreboff 2023 NEJM Table S14 (hyperesthesia family): placebo 1.4%, 1 mg 1.4%, 4 mg 6.1%, 8 mg 2.9% (slow ramp) vs 14.3% (fast ramp), 12 mg 12.9%. TRIUMPH-1 adverse-event-of-special-interest slide: 0.9 / 5.1 / 12.3 / 12.5% at placebo / 4 / 9 / 12 mg. TRIUMPH-4: 0.7 / 8.8 / 20.9% at placebo / 9 / 12 mg. The 8 mg ramp-speed contrast is 1 event vs 5 events on n=35 per arm — directionally consistent with the GI escalation-speed finding, not independently significant.

¹⁸ Persistence of hunger-hormone adaptations for up to a year after major weight loss: Sumithran et al. 2011 NEJM 10.1056/NEJMoa1105816.

¹⁹ Retatrutide body composition — Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes & Endocrinology. 2025;13(8):674-684. 10.1016/S2213-8587(25)00092-0. Week-36 DXA measured total fat, lean, and visceral mass by dose; it did not compare titration paths.

²⁰ Thermogenic-gating mechanism and the route-discriminating panel — local T3 in thermogenic tissue is gated by DIO2, which amplifies intracellular T3 three- to four-fold on sympathetic stimulation, with TRβ driving UCP1 from there. Three retatrutide effects converge on that gate: FGF21 suppression (dose-ordered to −65.7% at 8 mg, and FGF21 supports DIO2 expression); continuous glucagon-receptor engagement (glucagon lowers T3 and raises rT3 in humans with no TSH change); and the energy deficit itself (72 h fasting cuts T3 approximately 30%). Two additional routes bypass thyroid: GLP-1-mediated increases in subcutaneous and leg blood flow shed heat at the skin, and peripheral GLP-1R signaling suppresses brown-fat thermogenesis via vagal afferents. Acute glucagon raises energy expenditure approximately 150-240 kcal/day with GLP-1 co-administration preserving the rise (Beji & Caron 2026 Neuroendocrinology 116:157-172, p167) — production and defense are separate terms. Route discrimination: the thyroid route predicts cold skin, a widened core-to-periphery gradient, and T3 down with rT3 up; the perfusion route predicts warm skin with cold sensation, a narrowed gradient, and an intact thyroid panel; a sensory-gain route predicts normal thermal measurements with shifted quantitative sensory thresholds. Onset timing separates them further — deficit tracks weight-loss velocity, glucagon tracks days after a dose step, perfusion and sensory gain track injection timing. Retatrutide trials (Jastreboff 2023 NEJM NCT04881760; Rosenstock 2023 Lancet NCT04867785; Sanyal 2024 Nature Medicine; posted TRIUMPH-1 and TRIUMPH-4 toplines) measured zero thyroid-axis endpoints; a T3/rT3 panel plus a skin-versus-core gradient in a user reporting cold is the cheapest discriminating measurement available. Note that TSH is unchanged on the glucagon route, leaving a TSH-first screen uninformative; Free T3 and rT3 must be ordered explicitly. The residual limitation runs one way only: DIO2 gates T3 intracellularly, and a normal Free T3 narrows toward perfusion without fully excluding impaired local thermogenesis.

²¹ Slow-titration evidence — Nauck MA, Punov V, Kang YM, Lim S. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. Diabetes, Obesity and Metabolism. 2026;28(5):4232-4242. 10.1111/dom.70613. Across nine incretin mimetics, nausea tolerance tracked escalation duration (r²=0.834; p=0.0010) and step count (r²=0.764; p=0.0045), while starting-dose fraction did not (p=0.093). Within tirzepatide, full escalation moved nausea ED50 from 15.6 to 78.7 mg/week and vomiting ED50 from 43.3 to 209 mg/week—about a fivefold tolerance shift. This supplies the class-level logic for more time and more steps.

²² Split-frequency calculation — one-compartment steady-state superposition using retatrutide’s approximately six-day half-life from Coskun 2022. With weekly dose held constant, q3d dosing uses 3/7 of the weekly amount per injection. The 43% excursion and approximately 19% peak reduction are model outputs, not measured trial endpoints.